# OnCo record stc-1010 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/stc-1010/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "stc-1010" ;
  schema:name "STC-1010"@en ;
  schema:description "STC-1010 is an experimental off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines from Brenus Pharma, in phase 1 trials for unresectable locally advanced or metastatic pMMR/MSS colorectal cancer."@en ;
  schema:url <https://onco.cc/drugs/stc-1010/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.brenus-pharma.com/science-innovation>, <https://www.brenus-pharma.com/articles/brenus-pharma-esmo-2026-stc-1010-phase-1a-results>, <https://www.brenus-pharma.com/articles/brenus-pharma-esmo-2026-stc-1010-phase-1a-results>, <https://clinicaltrials.gov/api/v2/studies/NCT06934538>, <https://clinicaltrials.gov/search?intr=STC-1010> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Off-the-shelf in vivo immunotherapy from stimulated, inactivated allogeneic cancer cell lines (the company calls it an in vivo DC-engager)" ;
  onco:cancers <https://onco.cc/cancers/colorectal/> ;
  onco:companies <https://onco.cc/companies/brenus-pharma/> ;
  onco:trials <https://onco.cc/trials/nct06934538/> .